

ADAP Medical Advisory Committee

January 17, 2024 Gathering Notes

1) Welcome and Rollcall

I. Welcome:

Gathering opened by Joseph Lagrama, ADAP Branch Chief

II. Introductions:

MAC Members, CDPH, and Magellan

MAC Members in Attendance

Lucas Hill, David Lewis, Cliff Okada, Joanna Eveland, Laveeza Bhatti, Arlet Arratoonian, Danny Toub, Cliff Okada, Stephen O'Brien, David Grelotti

CDPH/Office of AIDS staff in Attendance

Philip Peters, Joseph Lagrama, James Vo, Alej Contreras, Becca Parks

MAC Members not in Attendance

Michelle Sherman, Glenn San Agustin

Magellan Representatives in Attendance

Carrie Holden

2) ADAP / MAC Updates

I. Medications added to the ADAP formulary and updates:

- Medications that will be discussed in 2024: dental and heart failure prevention.
- CDPH is currently following the clinical trial of lenacapavir for HIV prevention pre-exposure prophylaxis (PrEP) and will update the members with any new information received.
- Anticoagulants, vitamin D, alendronate (Fosamax) and XR-Buprenorphine (Sublocade®) are currently under the cost analysis process.
- PENBRAYA meningococcal and the COVID-19 Novavax vaccines are currently under the cost analysis process.
- Insulin treatment products – insulin lispro (Humalog® and Admelog®), regular insulin (Humulin® R and Novolin® R), insulin glargine (Lantus®), insulin detemir (Levemir®), insulin aspart (NovoLog®), and insulin glargine (Basaglar®) – and diabetic products – pen needles, glucometers, control solutions, lancing devices, insulin delivery devices, test strips, ketone test strips for urine and blood glucose, lancets, and syringes – were added to the ADAP formulary to align with Medi-Cal.
- COVID-19 vaccines Comirnaty® (Pfizer) and Spikevax® (Moderna) were added to the ADAP formulary.
- Oral extended-release paliperidone (INVEGA) was added to the ADAP formulary.
- Hypertension medications amlodipine, atenolol, carvedilol, diltiazem, enalapril, metoprolol succinate, metoprolol tartrate, nifedipine, and olmesartan were added to the ADAP formulary.
- Respiratory Syncytial Virus (RSV) vaccine was added to the ADAP formulary.

II. Medications removed from the ADAP formulary:

- Management Memo 2023-21: *Removal of Medications from the ADAP formulary* was released and posted to CDPH website to advise of all medications that were removed from the ADAP formulary in 2023.

III. Update on the medications discussed during the October 2023 MAC Gathering:

- None

3) **Medication Discussion**

- I. No public comments.

4) **PrEP-AP Formulary**

- I. Cabotegravir (Apretude) was added to the PrEP-AP Formulary for Clients with Confidentiality Concerns and Minor Clients. Additionally, PrEP-AP clients with insurance can receive wrap-around coverage for Apretude after they have exhausted coverage available from insurance and the ViiVConnect pharmaceutical assistance program.

5) **Opportunistic Infection Treatments**

- I. No public comments.

6) **Magellan Rx Presentation**

- I. Carrie Holden presented on:

- Bipolar Disorder Medication Overview
- Dulaglutide Utilization Review

7) **Close of Meeting**

- I. The next ADAP MAC gathering is scheduled for April 17, 2024, from 7:30 a.m. to 9:00 a.m.

8) **Action Items**

Action Items	Owners
Review data of the regimen for people requesting carbamazepine	Carrie Holden
Dulaglutide Utilization review in six months and dosing information	Carrie Holden